NEWS

WIRES

OTHER

Nutra Pharma to Exhibit at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C.

"The IDGA Battlefield Healthcare Summit is one of the most highly regarded forums for discussing best practices and next generation combat medicine and rehabilitative care," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We believe this summit provides an excellent venue for introducing our Nyloxin branded pain relievers to the military healthcare community," he concluded.

Nutra Pharma first introduced Nyloxin OTC in November 2009 as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the Company introduced Nyloxin Rx in October 2009 as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function.

Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.

http://www.NutraPharma.com

http://www.Nyloxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above statements pertaining to the 12^th IDGA Battlefield Healthcare Summit should not be construed as an indication in any way whatsoever of: (a) the Company's financial value; and/or (b) any predictive value of the Company's future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com